• news.cision.com/
  • Attana/
  • Attana features in Pharma Publications with AVA™ as a leading-edge solution for improved SARS-CoV-2 testing and immunity profiling

Attana features in Pharma Publications with AVA™ as a leading-edge solution for improved SARS-CoV-2 testing and immunity profiling

Report this content

Recently, an article about Attana’s first non-clinical in vitro diagnostic (IVD) device, Attana Virus Analytics – AVA™, was published in IBI (International Biopharmaceutical Industry). The article explains how AVA could help provide invaluable insights when assessing patient immunity for SARS-CoV-2.

A brief summary of the article:

The Challenge of Assessing SARS-CoV-2 Immunity
One of the main challenges with SARS-CoV-2 is assessing patient immunity. Conventional testing methods focuse on the binary presence of virus-specific antibodies (e.g. IgA, IgM and IgG). However, SARS-CoV-2 immunity assessments requires a more nuanced analysis of the immune response, since a significant number of SARS-CoV-2 positive individuals have not developed any discernable antibody counts post-infection.  

A Solution for Improved SARS-CoV-2 Immunity Assessing
Attana Virus Analytics – AVA™ is a generic IVD device for non-clinical laboratory use, consisting of Attana’s proprietary third-generation biosensor, various assays, and reagents. This technology enables AVA™ to take a broader approach when assessing immunity compared with the most prevalent virus diagnostics tools that are traditional based on ELSIA assays. By comparing an individual’s immune responses in a series of tests, a full patient immunity profile can be established and manifested. The AVA™ platform could therefore provide invaluable insights on an individual patient level, as well as the most suitable vaccination programmes based on the population’s immunity.

Nest steps for AVA™ platform
Although Attana recently entered the IVD market, our biosensor instruments have been used by Big Pharma, biotech companies, and academia for over 18 years and been highlighted in over 130 peer-reviewed publications. Attana have recently initiated a regulatory approval process for the AVA™ platform and will continue to engage in cross-disciplinary development of a point-of-care IVD device with AI-enabled automated analytic capabilities.    

Read the full article here.

For more information, please contact:

Teodor Aastrup, CEO Attana AB
+ 46 8 674 57 00

The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share price but is of general interest for the shareholders and hence should be communicated.

About Attana

Attana was founded in 2002 with the vision of in vitro characterization of molecular interactions mimicking in vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays and the Attana Virus Analytics (AVA) platform, a proprietary in vitro diagnostics (IVD) tool. Attana products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about our latest services and products, please visit www.attana.com or contact sales@attana.com